Home » Canadian Generic Firms See Harm in Stronger IP Rights for Brand Companies
Canadian Generic Firms See Harm in Stronger IP Rights for Brand Companies
February 16, 2011
While a new report shows that Canada’s intellectual property rights must be strengthened to attract interest and investment in the pharmaceutical sector, the generic drug sector believes that could mean increased prescription costs for provincial governments and patients.
To View This Article:
Subscribe To International Pharmaceutical Regulatory Monitor